Advertisement
Screener

TVARDI THERAPEUTICS, INC. (TVRD) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

2.8 / 5 stars · 68/120 Roast Me

TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate

TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate of 70.50% for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-08.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate · last filed 2026-05-08

  • TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2026-03-31 was 70.50%.
  • TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2025-09-30 was 67.72%.
  • TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-06-30 was 89.80%.
  • TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for the quarter ending 2024-03-31 was 89.60%.
  • TVARDI THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, fair value assumptions, expected volatility rate for fiscal 2024 was 73.79%.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 12 month
2026-03-3170.50%
10-Q · filed 2026-05-08
2025-09-3067.72%
10-Q · filed 2025-11-13
2024-12-3173.79%
10-K · filed 2026-03-31
2024-09-3073.79%
10-Q · filed 2025-11-13
2024-06-3089.80%
10-Q · filed 2024-08-14
73.79%
10-Q · filed 2025-08-14
2024-03-3189.60%
10-Q · filed 2025-05-13
2023-09-3080.80%
10-Q · filed 2024-11-14
2019-09-3071.80%
10-Q · filed 2020-11-09
2018-03-3185.90%
10-Q · filed 2019-05-07
2017-06-3083.30%
10-Q · filed 2018-08-07
2016-09-3071.90%
10-Q · filed 2016-11-04
2015-09-3064.10%
10-Q · filed 2016-11-04
2015-06-3064.00%
10-Q · filed 2016-08-04
2014-09-3065.00%
10-Q · filed 2015-11-09
2014-06-3065.00%
10-Q · filed 2015-08-10

Similar stocks

Stock NameCountryMarket CapPE Ratio
Vyome Holdings, Inc (HIND)United States$0.014B-1.38
BullFrog AI Holdings, Inc. (BFRG)United States$0.014B
ACTUATE THERAPEUTICS, INC. (ACTU)United States$0.015B
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B
LISATA THERAPEUTICS, INC. (LSTA)United States$0.014B-2.13
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Vistagen Therapeutics, Inc. (VTGN)United States$0.013B-0.14
MUSTANG BIO, INC. (MBIO)United States$0.013B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
AEON Biopharma, Inc. (AEON)United States$0.013B-0.36